Nuvastatic

Fatigue

Natureceuticals Sdn BhdPhase 3Active

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 95/ 100

Competitive context

3 Active assets in the Fatigue cohort.

Asset / Sponsor	Phase	Rating
Sra-333 Wake Forest University Health Sciences	Phase 2	B
(D)-LIMONENE Pure Green	Phase 2	CCC
PALMITIC MONOETHANOLAMIDE Pure Green	Phase 2	CCC
Mitoquinol mesilate VA Office of Research and Development	Phase 1/2	CCC
Cediranib City of Hope Medical Center	Phase 1	CC

View all 12 →

Same molecule, other indications

Nuvastatic is also rated in:

Chemotherapy, AdjuvantDormant

BB

Indicative ·

64 / 100

Quality of LifeDormant

BB

Indicative ·

64 / 100

Breast NeoplasmsDormant

CCC

Indicative ·

54 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.